Latest News and Press Releases

Arcutis announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, for the treatment of atopic dermatitis

Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

Arcutis today announced the promotion of Todd Tucker to senior vice president and Chief Human Resources Officer.

These findings are the first to characterize the unique molecular profile of seborrheic dermatitis

Arcutis today announced the closing of its previously announced underwritten public offering.

Arcutis today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting.

Arcutis and Sato today announced that the companies have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan.

Arcutis today reported financial results for the quarter ended September 30, 2023, and provided a business update.

Arcutis will host a conference call and webcast at 8:30 a.m. ET on 11/3/2023 to report its third quarter financial results and provide a business update.

WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing...